The SOLiD ALLIANCE nBIU Headend delivers double the capacity in 70 percent less space for high-performance in-building connectivity – SOLiD, the cellular in-building coverage leader, introduced the latest addition to the SOLiD ALLIANCE 5G distributed antenna system (DAS) platform for multi-operator cellular networks. The new BTS Interface Unit (nBIU) is the fourth-generation headend for the […]
Delivering Essential Data Center Capacity in Supply-ConstrainedDowntown Atlanta Market RadiusDC, a leading provider of highly connected, innovative and resilient data center solutions, has announced the acquisition of the mission-critical carrier-hotel facility located at 55 Marietta Street NW in Downtown Atlanta. https://mma.prnewswire.com/media/2480705/RadiusDC_Logo.jpg The 403,000 square-foot, 21-story carrier hotel is strategically positioned at the hub of connectivity
— Intensifying AI demands continue to proliferate across aerospace and defense, automotive, consumer electronics, data center, industrial automation andMedTech — Advances continue in thermal management, power efficiency, optical connectivity, electrification, personalization along with modular architecture and open standards — Continued collaboration needed to ensure supply optionality, localized manufacturing and pragmatic, AI-driven data intelligence to drive
(NASDAQ:GURE), SHOUGUANG, China, Dec. 02, 2025 (GLOBE NEWSWIRE) — Gulf Resources, Inc. (“Gulf Resources,” “we,” or the “Company”) announced today that it received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq's requirement under Listing Rule 5550(a)(2). The hearing before the Hearings Panel
(NASDAQ:BFRI),(NASDAQ:BFRIW), sNDA for treatment of sBCC with Ameluz(R)-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025 First Phase 3 PDT study in patients with sBCC in the United States submitted to FDA Primary and key secondary endpoints met with high statistical significance (p <0.0001) Favorable recurrence outcomes at one-year follow-up BCC
(CNSX:BLO.CN),(Pinksheets:BLOZF),(PinkSheets:BLOZF),(CNSX:BLO),(Boerse Frankfurt – Freiverkehr:8CT), VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is pleased to announce that it has entered into a second sales agreement for its BreathLogix unmanned alcohol screening technology with an
(NASDAQ:PALI), Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic
PARADISE VALLEY, Ariz., Dec. 02, 2025 (GLOBE NEWSWIRE) — Semiconductor manufacturer, IceMOS Technology Corporation , today announced a significant expansion of its global footprint with the establishment of IceMOS Technology Hong Kong Limited within the prestigious Hong Kong Science Park. This strategic move provides robust regional support for sales, field applications engineering and supply chain
Cannabix Technologies Strengthens Presence in Maritime Market with Repeat BreathLogix Alcohol Screening Device Order GlobeNewswire December 02, 2025 VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is pleased to announce that it has entered
Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development GlobeNewswire December 02, 2025 Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”